Freeze and fight: new combo tackles early lung cancer without surgery
NCT ID NCT07064876
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tests whether combining cryoablation (freezing the tumor) with the immunotherapy drug serplulimab can treat early-stage non-small cell lung cancer in people who cannot have surgery or radiation. Twenty-five adults with stage Ia NSCLC will receive one cryoablation procedure followed by up to six doses of serplulimab. The study will measure how many patients' tumors shrink or disappear, and track survival and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
serplulimab (a PD-1 inhibitor immunotherapy) and cryoablation (a procedure that freezes and destroys tumor tissue)
What this could lead to
If it works, this combination could offer a non-surgical treatment option for early-stage lung cancer, potentially controlling the disease and improving survival.
What could go wrong
This is a small, early-phase trial with only 25 participants and no comparison group, so results may not apply broadly. The immunotherapy can cause immune-related side effects, and the freezing procedure carries risks like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Affiliated to Fudan University, No. 180 Fenglin Road, Xuhui District,
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••